» Articles » PMID: 20452280

Bacteriophage Endolysins: a Novel Anti-infective to Control Gram-positive Pathogens

Overview
Specialty Microbiology
Date 2010 May 11
PMID 20452280
Citations 197
Authors
Affiliations
Soon will be listed here.
Abstract

Endolysins (or lysins) are highly evolved enzymes produced by bacteriophage (phage for short) to digest the bacterial cell wall for phage progeny release. In Gram-positive bacteria, small quantities of purified recombinant lysin added externally results in immediate lysis causing log-fold death of the target bacterium. Lysins have been used successfully in a variety of animal models to control pathogenic antibiotic-resistant bacteria found on mucosal surfaces and infected tissues. Their specificity for the pathogen without disturbing the normal flora, the low chance of bacterial resistance, and their ability to kill colonizing pathogens on mucosal surfaces, a capacity previously unavailable, make them ideal anti-infectives in an age of mounting resistance. Here we review the current literature showing the effectiveness of these enzymes in controlling a variety of infections.

Citing Articles

Phage-derived proteins: Advancing food safety through biocontrol and detection of foodborne pathogens.

Choi D, Ryu S, Kong M Compr Rev Food Sci Food Saf. 2025; 24(2):e70124.

PMID: 39898971 PMC: 11891642. DOI: 10.1111/1541-4337.70124.


Novel Anti-Microbial/Anti-Inflammatory Combination Improves Clinical Outcome of Bacillus cereus Endophthalmitis.

Mursalin M, Coburn P, Longoria-Gonzalez L, Astley R, Fischetti V, Callegan M Invest Ophthalmol Vis Sci. 2025; 66(1):39.

PMID: 39813055 PMC: 11741065. DOI: 10.1167/iovs.66.1.39.


Structural and functional analysis reveals the catalytic mechanism and substrate binding mode of the broad-spectrum endolysin Ply2741.

Wang S, Li X, Ma J, Duan X, Wang H, Wang L Virulence. 2025; 16(1):2449025.

PMID: 39810299 PMC: 11740692. DOI: 10.1080/21505594.2024.2449025.


Recombinant design of the enzymatically active domain of phage Enc34 endolysin to improve its activity against Gram-negative bacteria.

Kazaka T, Zrelovs N, Akopjana I, Bogans J, Jansons J, Dislers A FEMS Microbiol Lett. 2024; 371.

PMID: 39673269 PMC: 11657235. DOI: 10.1093/femsle/fnae103.


A novel chimeric endolysin Cly2v shows potential in treating streptococci-induced bovine mastitis and systemic infections.

Wang S, Li X, Ji J, Li X, Zhu H, Duan X Front Microbiol. 2024; 15:1482189.

PMID: 39493846 PMC: 11527626. DOI: 10.3389/fmicb.2024.1482189.


References
1.
OFlaherty S, Coffey A, Edwards R, Meaney W, Fitzgerald G, Ross R . Genome of staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive bacteria with a low G+C content. J Bacteriol. 2004; 186(9):2862-71. PMC: 387793. DOI: 10.1128/JB.186.9.2862-2871.2004. View

2.
Grandgirard D, Loeffler J, Fischetti V, Leib S . Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis. 2008; 197(11):1519-22. DOI: 10.1086/587942. View

3.
Young I, Wang I, Roof W . Phages will out: strategies of host cell lysis. Trends Microbiol. 2000; 8(3):120-8. DOI: 10.1016/s0966-842x(00)01705-4. View

4.
Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M . Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother. 2005; 11(5):211-9. DOI: 10.1007/s10156-005-0408-9. View

5.
Djurkovic S, Loeffler J, Fischetti V . Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother. 2005; 49(3):1225-8. PMC: 549239. DOI: 10.1128/AAC.49.3.1225-1228.2005. View